Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer

Inclusion Criteria

• •1. Signed informed-consent form;
• •2. Treatment-naive PDAC with histological or cytological diagnosis;
• •3. Resectable pancreatic cancer stage II and partial stage III defined according to the National Comprehensive Cancer Network definitions;
• •4. Age≥18 years old and ≤70 years old;
• •5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
• •6. BMI≥18.5 and NRS2002score\<3;
• •7. Expected survival over 3 months;
• •8. Spared organ function satisfying the following laboratory data:leucocyte≥3.0x109/L,neutrophils≥1.5x109/L, hemoglobin≥ 9g/dL, platelets ≥100x109/L, total bilirubin ≤ 1.5 ULN; AST and ALT≤ 2.5 ULN; serum creatinine≤1.5ULN; PT and INR≤ 2.5 ULN;